Details about Ya-Chen Tina Shih

Access statistics for papers by Ya-Chen Tina Shih.

Last updated 2023-11-20. Update your information in the RePEc Author Service.

Short-id: psh344

Journal Articles

2020

1. Simple Quasi-Bayes Approach for Modeling Mean Medical Costs
   The International Journal of Biostatistics, 2020, 16, (1), 10
   Also in The International Journal of Biostatistics, 2020, 16, (1), 10 (2020)

2019

2. Economic Burden of Renal Cell Carcinoma—Part I: An Updated Review
   PharmacoEconomics, 2019, 37, (3), 301-331 View citations (1)
3. Rising Economic Burden of Renal Cell Carcinoma among Elderly Patients in the USA: Part II—An Updated Analysis of SEER-Medicare Data
   PharmacoEconomics, 2019, 37, (12), 1495-1507

2018

4. Costs of Cancer Care for Elderly Patients with Neuroendocrine Tumors
   PharmacoEconomics, 2018, 36, (8), 1005-1013
5. Price Transparency for Whom? In Search of Out-of-Pocket Cost Estimates to Facilitate Cost Communication in Cancer Care
   PharmacoEconomics, 2018, 36, (3), 259-261 View citations (1)
6. Semiparametric Estimation of Longitudinal Medical Cost Trajectory
   Journal of the American Statistical Association, 2018, 113, (522), 582-592 View citations (1)
7. State insurance mandates and off‐label use of chemotherapy
   Health Economics, 2018, 27, (1), e55-e70

2017

8. Regression-Based Approaches to Patient-Centered Cost-Effectiveness Analysis
   PharmacoEconomics, 2017, 35, (7), 685-695 View citations (2)

2016

9. Therapeutic substitutions in the midst of new technology diffusion: The case of treatment for localized prostate cancer
   Social Science & Medicine, 2016, 151, (C), 110-120 View citations (2)

2015

10. Predicting the EQ-5D-3L Preference Index from the SF-12 Health Survey in a National US Sample
    Medical Decision Making, 2015, 35, (7), 888-901 View citations (1)
11. The Association between Patient-Centered Attributes of Care and Patient Satisfaction
    The Patient: Patient-Centered Outcomes Research, 2015, 8, (2), 187-197

2014

12. Cost-Effectiveness Analyses of Targeted Oral Anti-Cancer Drugs: A Systematic Review
    PharmacoEconomics, 2014, 32, (7), 651-680

2012

13. Physicians' perception of demand‐induced supply in the information age: a latent class model analysis
    Health Economics, 2012, 21, (3), 252-269 View citations (7)

2010

14. A flexible two-part random effects model for correlated medical costs
    Journal of Health Economics, 2010, 29, (1), 110-123 View citations (14)
15. Comparisons of changes over time in per capita health expenditures across racial and ethnic groups
    International Journal of Public Policy, 2010, 6, (3/4), 172-189

2007

16. A Cost-Effectiveness Analysis of First-Line Controller Therapies for Persistent Asthma
    PharmacoEconomics, 2007, 25, (7), 577-590
17. Use of Bayesian Net Benefit Regression Model to Examine the Impact of Generic Drug Entry on the Cost Effectiveness of Selective Serotonin Reuptake Inhibitors in Elderly Depressed Patients
    PharmacoEconomics, 2007, 25, (10), 843-862 View citations (1)

2006

18. Do Pharmacogenomic Tests Provide Value to Policy Makers?
    PharmacoEconomics, 2006, 24, (12), 1173-1177

2005

19. Impact of Generic Drug Entry on Cost-Effectiveness Analysis
    Medical Decision Making, 2005, 25, (1), 71-80 View citations (4)

2003

20. Sociological influences on antidepressant prescribing
    Social Science & Medicine, 2003, 56, (6), 1335-1344 View citations (7)